Dr. Valliant founded a national centre of excellence with the expertise to move novel probes from the lab to the clinic – the Centre for Probe Development and Commercialization (CPDC) – supplies probes for a number of clinical trials and has launched a new company, Fusion Pharmaceuticals.

The Centre for Probe Development and Commercialization (CPDC) is unique in that it has expertise in all areas related to the development, translation and commercialization of molecular imaging probes.

Molecular imaging probes and associated technologies have the potential to revolutionize health care. Probes can accelerate and support drug discovery and the development of new compounds by providing researchers with the chance to monitor the impact of medications at a molecular level, leading to personalized treatments for diseases like cancer. The CPDC is helping to realize that potential by producing probes for early disease detection and characterization and for drug discovery, including offering in-house expertise and probe production services.

Government and university investment in molecular imaging probe research and development has led to exciting and innovative Canadian discoveries in the field. Unfortunately, moving these probes and tools from university labs to hospitals and clinics has proved a challenge.

To meet that challenge, the Centre is focused on three main areas in molecular imaging probe development:

  • CPDC experts in chemistry, biology, physics and nuclear imaging are able to develop and test emerging probes and associated technologies, identifying those with the greatest promise for successful commercialization.
  • The CPDC also employs experts in quality assurance, manufacturing and regulatory affairs, which are needed to get new agents from the lab into clinical trials.
  • Fostering strong industry partnerships allows the CPDC to attract national and international investment and faster commercialization and job creation.

As a Centre of Excellence for Commercialization and Research, the CPDC receives federal investment through the Networks of Centres of Excellence program, the Ontario Institute for Cancer Research and multiple industry partners. To find out more, visit www.imagingprobes.ca